Skip to main content
Caplight Logo









Speclipse

Speclipse

Private
Seongnam-siHealthcare & Life Scienceshttps://speclipse.com/

Last Round

Private Equity

Jul 1, 2024

Total Funding Raised

$39.1M

Company Overview

Speclipse is a medical technology company that develops AI-powered laser spectroscopy systems for skin cancer diagnosis and aesthetic medical applications.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging, Medical AI

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

medical laserskin cancer screeninglaser-induced plasma spectroscopyLIPSmedical AIdermatology diagnostic toolnon-invasive biopsyaesthetic laserAI diagnostic assistantmedtechpoint of care diagnosticspicosecond laserskin lesion analysisclinical triageAI copilot for doctors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Speclipse Comparables

Compare Speclipse with similar companies based on industry and business-model similarity.

Speclipse comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DermaSensor, Inc.
86%
Vita Imaging Inc.
84%
Scibase Holding
80%

Speclipse Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityJul 1, 2024
Series AAug 19, 2021
Corporate FundingNov 5, 2019
SeedNov 1, 2016

Key People

Founding team and executive leadership

Wanki Min

CTO, Co-founder

Founding Team

Sung Hyun Pyun

Founder and CEO

Founding Team

Sean Min

COO

Executive Team

Speclipse Investors

Notable investors and investment history

Speclipse investors
InvestorRounds
InterVestSeed
Lindeman Asia InvestmentCorporate Funding
BNH INVESTMENTSeries A
K2 Investment PartnersPrivate Equity
SBVASeed
JB InvestmentSeed
Signite PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2016

    $2.6M raised from InterVest, JB Investment, and SBVA.

Speclipse Filings

Explore SEC and related filing metadata, where available.

Speclipse filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Speclipse's valuation, stock price, and market status.

Is Speclipse a public or private company?

Speclipse is a private company.

What is the current stock price of Speclipse?

Speclipse is a private company with no public stock price. No recent secondary market data is available.

How much is Speclipse worth (valuation)?

Valuation information for Speclipse is not publicly available.

Can I buy Speclipse stock?

Speclipse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Speclipse's last funding round?

Speclipse's most recent funding round was Private Equity on July 1, 2024.

Who are the main investors in Speclipse?

Key investors in Speclipse include Signite Partners.

Will Speclipse IPO soon?

No public IPO plans have been announced for Speclipse.

How can I track Speclipse secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Speclipse's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeongnam-si
Employee Range9
Year Founded2015
Last FundingJul 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?